NovaBridge Biosciences (NBP) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tiziana Life Sciences (TLSA) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 44.1% versus a loss of 71.2%. Over five years, TLSA leads with a -21.2% price change compared with -97.9% for NBP. NovaBridge Biosciences is the larger company by market cap ($161.8 million vs $151.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | TLSA |
|---|---|---|
| Share price | $1.40 | $1.19 |
| Market cap | $161.82M | $151.44M |
| 1-day change | +1.82% | +5.31% |
| YTD return | -64.95% | -20.13% |
| 1-year return | -71.24% | -44.13% |
| 5-year return | -97.88% | -21.19% |
| EPS (TTM) | $-0.70 | $-0.17 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.79 | $2.25 |
| 52-week low | $1.31 | $0.76 |
| Distance from 52-week high | -79.46% | -47.11% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +545.16% | +570.59% |
| Average volume | 381.40K | 720.16K |
| Shares outstanding | 116.00M | 127.26M |
| Employees | 30 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLSA has outperformed NBP by 27.1 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Health Care · Biotechnology: Pharmaceutical Preparations · 30 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
NBP vs TLSA FAQ
Which is bigger, NovaBridge Biosciences or Tiziana Life Sciences?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $161.82M compared with $151.44M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, NBP or TLSA?
TLSA returned -44.13% over the past 12 months, compared with -71.24% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.